share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  08/26 08:01

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics Ltd., a foreign private issuer, has reported to the United States Securities and Exchange Commission (SEC) in its Form 6-K filing for August 2024. The company had previously been notified on June 21, 2024, of its non-compliance with Nasdaq's Listing Rule 5550(b), as its stockholders' equity was below the minimum requirement of $2,500,000. In response, NeuroSense Therapeutics requested a hearing with the Nasdaq Hearings Panel, which took place on August 1, 2024. During the hearing, the company presented a plan to regain compliance. On August 25, 2024, NeuroSense Therapeutics received a favorable decision from the Panel, granting an exception to remain listed on the Nasdaq Capital Market until October 31, 2024. This extension provides the company with additional time to meet the listing rule's conditions. The Form 6-K filing is also incorporated by reference into the company's registration statements on Form F-3 and Form S-8, as filed with the SEC.
NeuroSense Therapeutics Ltd., a foreign private issuer, has reported to the United States Securities and Exchange Commission (SEC) in its Form 6-K filing for August 2024. The company had previously been notified on June 21, 2024, of its non-compliance with Nasdaq's Listing Rule 5550(b), as its stockholders' equity was below the minimum requirement of $2,500,000. In response, NeuroSense Therapeutics requested a hearing with the Nasdaq Hearings Panel, which took place on August 1, 2024. During the hearing, the company presented a plan to regain compliance. On August 25, 2024, NeuroSense Therapeutics received a favorable decision from the Panel, granting an exception to remain listed on the Nasdaq Capital Market until October 31, 2024. This extension provides the company with additional time to meet the listing rule's conditions. The Form 6-K filing is also incorporated by reference into the company's registration statements on Form F-3 and Form S-8, as filed with the SEC.
NeuroSense Therapeutics Ltd.,一家外國私募發行人,在其遞交的2024年8月6-k文件中向美國證券交易委員會(SEC)報告。該公司此前於2024年6月21日收到通知,稱其股東權益低於納斯達克的5550(b)上市規則的最低要求,即250萬美元。作爲回應,NeuroSense Therapeutics要求與納斯達克聽證會小組進行聽證,於2024年8月1日舉行了會議。在聽證會上,該公司提出了恢復合規性的計劃。2024年8月25日,NeuroSense Therapeutics獲得了小組的有利決定,獲得了豁免權,允許其繼續在納斯達克資本市場上市,直至2024年10月31日。這一延期爲公司提供了額外的時間來滿足上市規則的條件。6-k文件也被納入了公司在Form F-3和Form S-8上向SEC提交的註冊聲明中。
NeuroSense Therapeutics Ltd.,一家外國私募發行人,在其遞交的2024年8月6-k文件中向美國證券交易委員會(SEC)報告。該公司此前於2024年6月21日收到通知,稱其股東權益低於納斯達克的5550(b)上市規則的最低要求,即250萬美元。作爲回應,NeuroSense Therapeutics要求與納斯達克聽證會小組進行聽證,於2024年8月1日舉行了會議。在聽證會上,該公司提出了恢復合規性的計劃。2024年8月25日,NeuroSense Therapeutics獲得了小組的有利決定,獲得了豁免權,允許其繼續在納斯達克資本市場上市,直至2024年10月31日。這一延期爲公司提供了額外的時間來滿足上市規則的條件。6-k文件也被納入了公司在Form F-3和Form S-8上向SEC提交的註冊聲明中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息